CL2022001722A1 - Derivados carboxi con propiedades antiinflamatorias - Google Patents

Derivados carboxi con propiedades antiinflamatorias

Info

Publication number
CL2022001722A1
CL2022001722A1 CL2022001722A CL2022001722A CL2022001722A1 CL 2022001722 A1 CL2022001722 A1 CL 2022001722A1 CL 2022001722 A CL2022001722 A CL 2022001722A CL 2022001722 A CL2022001722 A CL 2022001722A CL 2022001722 A1 CL2022001722 A1 CL 2022001722A1
Authority
CL
Chile
Prior art keywords
inflammatory properties
carboxy derivatives
carboxy
derivatives
inflammatory
Prior art date
Application number
CL2022001722A
Other languages
English (en)
Inventor
Liam Cooke Michael
Cousin David
Colin Thor Fyfe Matthew
Michael WAUGH Thomas
Ahmed Saleh
De Simone Alessio
John Teobald Barry
Original Assignee
Sitryx Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sitryx Therapeutics Ltd filed Critical Sitryx Therapeutics Ltd
Publication of CL2022001722A1 publication Critical patent/CL2022001722A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)

Abstract

La invención se refiere a compuestos de la Fórmula (I) y a su uso para tratar o prevenir una enfermedad inflamatoria o una enfermedad asociada con una respuesta inmunitaria indeseable; en donde , RA1, RA2, RC y RD son como se definen en la presente.
CL2022001722A 2019-12-23 2022-06-22 Derivados carboxi con propiedades antiinflamatorias CL2022001722A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP19219531 2019-12-23
EP20162545 2020-03-11
EP20189623 2020-08-05
EP20205768 2020-11-04

Publications (1)

Publication Number Publication Date
CL2022001722A1 true CL2022001722A1 (es) 2023-03-03

Family

ID=74104118

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022001722A CL2022001722A1 (es) 2019-12-23 2022-06-22 Derivados carboxi con propiedades antiinflamatorias

Country Status (18)

Country Link
US (1) US20230219907A1 (es)
EP (1) EP4081511A1 (es)
JP (1) JP2023508142A (es)
KR (1) KR20220119425A (es)
CN (1) CN115066418A (es)
AU (1) AU2020412853A1 (es)
BR (1) BR112022011933A2 (es)
CA (1) CA3161424A1 (es)
CL (1) CL2022001722A1 (es)
CO (1) CO2022008652A2 (es)
CR (1) CR20220300A (es)
EC (1) ECSP22049370A (es)
IL (1) IL293982A (es)
JO (1) JOP20220162A1 (es)
MX (1) MX2022007846A (es)
PE (1) PE20221584A1 (es)
TW (1) TW202138356A (es)
WO (1) WO2021130492A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021022682A2 (pt) 2019-05-14 2022-02-22 Provention Bio Inc Métodos e composições para prevenir diabetes do tipo 1
EP4330231A1 (en) * 2021-04-26 2024-03-06 Sitryx Therapeutics Limited 2-methylene-4-oxo-butanoic acid drivatives for the treatment of inflammation
WO2022269251A1 (en) * 2021-06-22 2022-12-29 Sitryx Therapeutics Limited Acrylamide derivatives useful as anti-inflammatory agents
CN113499453B (zh) * 2021-07-20 2022-10-21 徐州医科大学 自噬抑制及抗炎联合温合光热诊疗剂及其制备方法与应用
WO2023017269A1 (en) 2021-08-11 2023-02-16 Sitryx Therapeutics Limited Derivatives of itaconic acid and their use as anti-inflammatory agents
WO2023247958A1 (en) 2022-06-22 2023-12-28 Sitryx Therapeutics Limited Oxadiazole derivatives, preparation process thereof and their use in treating inflammatory diseases
WO2024089421A1 (en) 2022-10-25 2024-05-02 Sitryx Therapeutics Limited Tetrazole derivatives
CN115819186B (zh) * 2023-02-14 2023-05-16 广东银珠医药科技有限公司 一种3,5-二氯苯甲醇的新型制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7798994A (en) * 1993-10-20 1995-05-08 Upjohn Company, The Pyrimidinones as antiarthritic and anti-inflammatories
PT2970101T (pt) 2013-03-14 2018-10-04 Alkermes Pharma Ireland Ltd Pró-fármacos de fumaratos e seu uso no tratamento de várias doenças
WO2014152263A1 (en) 2013-03-15 2014-09-25 Karyopharm Therapeutics Inc. Exo olefin-containing nuclear transport modulators and uses thereof
EP3416634A4 (en) 2016-02-15 2019-10-09 Artyomov, Maxim IMMUNOMODULATORY AGENTS AND METHODS OF USE
EP3668497A4 (en) 2017-08-14 2021-04-28 Washington University METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER, INFLAMMATION, OR IMMUNE-REACTION-ASSOCIATED DISEASES
CN110731955B (zh) 2019-10-28 2023-05-02 中山大学 衣康酸二甲酯在预防和治疗溃疡性结肠炎及其癌变中的应用

Also Published As

Publication number Publication date
JOP20220162A1 (ar) 2023-01-30
CO2022008652A2 (es) 2022-07-19
MX2022007846A (es) 2022-07-19
CR20220300A (es) 2022-08-23
JP2023508142A (ja) 2023-03-01
WO2021130492A1 (en) 2021-07-01
CA3161424A1 (en) 2021-07-01
TW202138356A (zh) 2021-10-16
IL293982A (en) 2022-08-01
BR112022011933A2 (pt) 2022-09-06
ECSP22049370A (es) 2022-07-29
US20230219907A1 (en) 2023-07-13
EP4081511A1 (en) 2022-11-02
AU2020412853A1 (en) 2022-05-26
PE20221584A1 (es) 2022-10-06
KR20220119425A (ko) 2022-08-29
CN115066418A (zh) 2022-09-16

Similar Documents

Publication Publication Date Title
CL2022001722A1 (es) Derivados carboxi con propiedades antiinflamatorias
ECSP21086530A (es) Derivados de ácido itacónico y usos de estos en el tratamiento de una enfermedad inflamatoria asociada con una respuesta inmunitaria indeseable
CY1125110T1 (el) Ενωσεις δι-κυκλικου-συντηγμενου ετεροαρυλιου ή αρυλιου και η χρηση αυτων ως αναστολεις irak4
CY1124663T1 (el) Αντιιικα παραγωγα ν4-υδροξυκυτιδινης
EA201691194A1 (ru) Стимуляторы ргц
ECSP19070336A (es) Arn terapéutico
BR112017009648A2 (pt) composto, métodos para tratamento de doenças alérgicas ou outras condições inflamatórias ou prevenção de doença, de rinite alérgica ou asma, composição, e, uso de um composto.
CU20150119A7 (es) 3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de idh mutante
UY36544A (es) Derivados de 4h-pirrol[3,2-c]piridin-4-ona
BR112016028288A2 (pt) ?composto, composição farmacêutica, métodos para tratamento de um indivíduo com uma doença ou condição e para inibir a quinase, e, uso de um composto?
CL2017001661A1 (es) Compuestos biciclicos fusionados para el tratamiento de una enfermedad.
EA201790627A1 (ru) СТИМУЛЯТОРЫ рГЦ
EA202091731A1 (ru) Ингибиторы аутотаксина и их применения
NI201500115A (es) Estra-1,3,5(10), 16-tetraeno-3-carboxamidas para la inhibición de la 17b-hidroxiesteroide deshidrogenasa (akr1 c3)
CR20160133A (es) Derivados de fenilalanina sustituidos
EA201691412A1 (ru) Гидроксиформамидные производные и их применение
CY1123722T1 (el) Ενεσιμα φαρμακευτικα σκευασματα λεφαμουλινης
NI201500175A (es) Compuestos nuevos para el tratamiento del cáncer
UY36217A (es) Compuestos piridona sustituídos, composiciones farmacéuticas y métodos de uso.
CL2019000487A1 (es) Derivado de triazolopirazinona útil como un inhibidor de pde1 humana.
CR20150659A (es) Derivados de prodroga de triazolpiridinas sustituidas
CO2019011227A2 (es) N-ariletil-2-aminoquinolin-4-carboxamidas sustituidas y su uso
EA201692371A1 (ru) 1h-1,8-нафтиридин-2-оны в качестве антипролиферативных соединений
CO2021014351A2 (es) Derivados de quinolina y su uso para el tratamiento del cáncer
EA201892585A1 (ru) 6-(БУТА-1,3-ДИИН-1-ИЛ)БЕНЗО[d]ТИАЗОЛЬНЫЕ ПРОИЗВОДНЫЕ